Corrigenda and Addenda

Correction: The Efficacy, Safety, and Efficiency of the Off-Label Use of Bevacizumab in Patients Diagnosed With Age-Related Macular Degeneration: Protocol for a Systematic Review and Meta-Analysis

João Estarreja[1*], PharmD; Priscila Mendes[1*], MSc, PharmD, PhD; Carina Silva[1,2*], BSc, MSc, PhD; Pedro Camacho[1*], BSc, MSc, PhD; Vanessa Mateus[1,3*], MSc, PharmD, PhD

[1]Health & Technology Research Center, Escola Superior de Tecnologia da Saúde, Instituto Politécnico de Lisboa, Lisbon, Portugal

[2]Centro de Estatística e Aplicações, Universidade de Lisboa, Lisbon, Portugal

[3]iMed.ULisboa, Faculdade de Farmacia, Universidade de Lisboa, Lisbon, Portugal

[*]all authors contributed equally

Corresponding Author:
Vanessa Mateus, MSc, PharmD, PhD
Health & Technology Research Center
Escola Superior de Tecnologia da Saúde
Instituto Politécnico de Lisboa
Avenida D João II
Lote 4.69.01
Lisbon, 1990-096
Portugal
Phone: 351 218980409
Email: vanessa.mateus@estesl.ipl.pt

In "The Efficacy, Safety, and Efficiency of the Off-Label Use of Bevacizumab in Patients Diagnosed With Age-Related Macular Degeneration: Protocol for a Systematic Review and Meta-Analysis" (JMIR Res Protoc 2023;12:e38658) the authors noted a missing Acknowledgments section. The Acknowledgments section has now been added to the published paper as follows:

The correction will appear in the online version of the paper on the JMIR Publications website on July 4, 2023, together with the publication of this correction notice. Because this was made after submission to PubMed, PubMed Central, and other full-text repositories, the corrected article has also been resubmitted to those repositories.

XSL•FO
RenderX

XSL•FO

RenderX